Loading...
XCNQ
DOSE
Market cap11mUSD
Jul 09, Last price  
0.12CAD
1D
4.35%
1Q
14.29%
IPO
-85.00%
Name

Rapid Dose Therapeutics Corp

Chart & Performance

D1W1MN
XCNQ:DOSE chart
P/E
P/S
5.85
EPS
Div Yield, %
Shrs. gr., 5y
11.32%
Rev. gr., 5y
29.71%
Revenues
3m
+33.00%
00000000000101,498755,2011,752,000718,2981,020,0002,085,1762,773,312
Net income
-3m
L-37.28%
-3,379-6,805-79,956-67,720-178,548-19,488-19,202-51,744-47,097-50,079-11,398,000-7,965,000-1,805,000-8,487,000-3,810,000-4,306,000-5,404,265-3,389,667
CFO
-270k
L-76.42%
-35,442-36,364-44,924-55,760-160,184-28,879-58,294-49,129-30,655-57,991-2,132,258-3,032,681-1,623,642-2,999,529-863,917-2,294,991-1,146,777-270,394

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Rapid Dose Therapeutics Corp., a life sciences enterprise based in Burlington, Canada, specializes in cutting-edge drug delivery systems aimed at enhancing health and well-being for individuals across Canada. Their core offering is the QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter remedies—directly into the bloodstream. The product line includes targeted solutions like QuickStrip energy, infused with caffeine; QuickStrip B12, providing vitamin B12; and QuickStrip sleep, which delivers melatonin. Furthermore, the company provides bespoke services encompassing product innovation, manufacturing, and strategic consultation to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing sectors. Rapid Dose Therapeutics also maintains a significant research partnership with McMaster University, jointly developing advanced biopolymer compositions for optimized thin-film drug delivery and pioneering an orally administered COVID-19 vaccine candidate.
IPO date
Dec 17, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑022025‑022024‑022023‑022022‑022021‑022020‑022019‑022017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT